Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ACST $2.70 - MC $28 million - Cash $20 million - has attractive orphan drug nearing Phase 3 readout, if positive this will be the next 10 bagger
Company Anticipates Completion of Patient Enrollment in the STRIVE-ON Trial in Late 2024 to Early 2025, with NDA Submission on Track for 1H Calendar 2025
Projected Cash Runway into Second Calendar Quarter 2026
LYRA $0.26 has $1+ cash per shr and to release phase 3 data next quarter - Market Cap $17 million -Cash balance $67,5 million
Primary focus continues to be on upcoming results from ENLIGHTEN 1 Phase 3 extension study in 4Q 2024 and ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients in 1H 2025, as planned
LYRA $0.26 has $1+ cash per shr and to release phase 3 data next quarter - Market Cap $17 million -Cash balance $67,5 million
Primary focus continues to be on upcoming results from ENLIGHTEN 1 Phase 3 extension study in 4Q 2024 and ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients in 1H 2025, as planned
ACST $2.65 -MC $27 m -Phase 3 data coming soon if positive this low floater going to $10 and more ....
Presentation
https://d1io3yog0oux5.cloudfront.net/_2c1a3f9f6fe3df87f7658ac20ee923d9/acastipharma/db/722/7897/pdf/Acasti+Corporate+Presentation.pdf
EYEN $0.59 has 2 approved drugs and a blockbuster in phase 3 with first data coming next quarter , this could hit 2 bucks and more with positive results
CNTB $1.20 trading massive under its cash and has 3 Phase 3 ready programs with best in class potential
KZR $0.62 has $2.47 Cash per share and 2 blockbusters in Phase 2
UNCY $0.70 -positive data and NDA submission in Q3 , stock still trading way under its cash balance
Unicycive Therapeutics Achieves Study Objective in Oxylanthanum Carbonate (OLC) Pivotal Clinical Trial
https://finance.yahoo.com/news/unicycive-therapeutics-achieves-study-objective-113000668.html
– Successfully Established Favorable Tolerability and Safety of OLC –
– New Drug Application (NDA) Submission Anticipated in Q3 2024 –
The global market opportunity for treating hyperphosphatemia is projected to be in excess of $2.5 billion in 2023, with the United States accounting for more than $1 billion of that total.
UNCY $0.63 -Phase 3 results this week , if positive the stock likely going to explode toward $3 and more
On Track to Provide Topline Data from the Ongoing Pivotal Clinical Trial with Oxylanthanum Carbonate (OLC) in Q2 2024
UNCY $0.65 - Phase 3 results within 2 weeks if positive this underpriced stock could explode toward 5 dollars
Slide Presentation
https://d1io3yog0oux5.cloudfront.net/_74e777549b63a9fda52514c560b86788/unicycive/db/1912/17746/pdf/Unicycive+Corporate+Presentation+-++June+2024+Final.pdf
UNCY $0.65 - Phase 3 results within 2 weeks if positive this underpriced stock could explode toward 5 dollars
Slide Presentation
https://d1io3yog0oux5.cloudfront.net/_74e777549b63a9fda52514c560b86788/unicycive/db/1912/17746/pdf/Unicycive+Corporate+Presentation+-++June+2024+Final.pdf
TFFP $2.40 - MC $7 m -has 2 Blockbuster which are phase 3 ready ,this low float stock is extremly underpriced
slide presentation (scroll down)
https://tffpharma.com/investors/
-TFF TAC (Tacrolimus Inhalation Powder) for lung transplantation with >$2 billion annual peak sales potential
-TFF VORI (Voriconazole Inhalation Powder) for serious pulmonary fungal nfections with >$1 billion annual peak sales potential
TFFP $2.40 - MC $7 m -has 2 Blockbuster which are phase 3 ready ,this low float stock is extremly underpriced
slide presentation (scroll down)
https://tffpharma.com/investors/
-TFF TAC (Tacrolimus Inhalation Powder) for lung transplantation with >$2 billion annual peak sales potential
-TFF VORI (Voriconazole Inhalation Powder) for serious pulmonary fungal nfections with >$1 billion annual peak sales potential
NRXP -MC $35 m - 2x Phase 3 results imminent expected during this month , a potential 10 bagger here with positive data readouts
upcoming milestones expected during Q2:
Release of top-line data from its trial of NRX-101 in Treatment Resistant Suicidal Bipolar Depression
Release of top-line data from Northwestern University's Department of Defense funded trial of the main component of NRX-101 in Chronic Pain
NDA filing for IV Ketamine for treatment of Suicidal Depression
NRXP -MC $35 m - 2x Phase 3 results imminent expected during this month , a potential 10 bagger here with positive data readouts
Upcoming milestones expected during Q2:
Release of top-line data from its trial of NRX-101 in Treatment Resistant Suicidal Bipolar Depression
Release of top-line data from Northwestern University's Department of Defense funded trial of the main component of NRX-101 in Chronic Pain
NDA filing for IV Ketamine for treatment of Suicidal Depression
NRXP up 16% - 2x Phase 3 readouts imminent expected during this month - market cap only $52 million
EYEN $0.59 -has 2x approved drugs and 2x Phase 3 Drugs including a potential blockbuster .. stock is super cheap at 28 million valuation a great reboundplay here
Eyenovia Announces Updated Strategy and Corporate Priorities to Focus on Shareholder Value Generation and Immediate Commercial Opportunities
https://finance.yahoo.com/news/eyenovia-announces-updated-strategy-corporate-110000476.html
EYEN $0.59 -has 2x approved drugs and 2x Phase 3 Drugs including a potential blockbuster .. stock is super cheap at 28 million valuation a great reboundplay here
Eyenovia Announces Updated Strategy and Corporate Priorities to Focus on Shareholder Value Generation and Immediate Commercial Opportunities
https://finance.yahoo.com/news/eyenovia-announces-updated-strategy-corporate-110000476.html
(NRXP) MC $50m -Phase 3 results imminent for their bipolar depression drug expected this month and another Phase 3 results from their chronic back pain trial also expected in the coming weeks . With positive results this low floater going to explode toward $20 currently trading at $5.20 .Check out their presentation below for more informations
Presentation
https://www.nrxpharma.com/wp-content/uploads/NRx-Corporate-Presentation.pdf
(NRXP) MC $50m -Phase 3 results imminent for their bipolar depression drug expected this month and another Phase 3 results from their chronic back pain trial also expected in the coming weeks . With positive results this low floater going to explode toward $20 currently trading at $5.20 .Check out their presentation below for more informations
Presentation
https://www.nrxpharma.com/wp-content/uploads/NRx-Corporate-Presentation.pdf
NRXP -MC $50m -Phase 3 results imminent for their bipolar depression drug expected this month and another Phase 3 results from their chronic back pain trial also expected in the coming weeks . With positive results this low floater going to explode toward $20 currently trading at $5.20 .Check out their presentation below for more informations
Presentation
https://www.nrxpharma.com/wp-content/uploads/NRx-Corporate-Presentation.pdf
CNTB $1.70 -3x blockbuster in Phase 3 while trading way under its cash balance
ASLN $0.68 - MC $11 m -Cash $30+ M - has Phase 3 asset and 2 Phase 2 programs ongoing with data readout expected in Q2 .. great reboundplay adter the drop from $2..
ASLN $0.68 - MC $11 m -Cash $30+ M - has Phase 3 asset and 2 Phase 2 programs ongoing with data readout expected in Q2 .. great reboundplay adter the drop from $2
ASLN $0.75 - MC $12 m - Cash $30+ m - has phase 3 asset and more in phase 2 ..terrible underprcied gem here
ASLN $0.75 - MC $12 m - Cash $30+ m has phase 3 asset and more in phase 2 ..terrible underprcied gem here
ASLN $0.69 hot reboundplay after the big drop yesterday ...has very low valuation of 11 million and an attractive phase 3 ready pipeline , could run back above $1
LPCN -MC $20 m -blockbuster phase 2 data readout coming this month and final results of depression drug coming in Q2 ,more informations in their presentation below . This could be the next 10 bagger
presentation
https://ir.lipocine.com/download/Corp+Deck_Lipocine+-+March+2024_Final.pdf
TCON running next bomb could be LPCN $3.30 - MC $18 million traind under its Cash of $25 million and to report final results for their depression drug in Q2 and Phase 2 data for their potential blockbuster targeting liver cirrhosis expected THIS month .both stock have 10 bagger potential
TCON $0.29 up 17% -- interim results from their cancer drug coming during this month - market cap still at laughable 13 milion
TCON $0.25 -interin data readout coming within days - market cap only $10 million
TCON $0.25 about to breakout -check this analysis out https://sih-st-charts.stocktwits-cdn.com/fit-in/500x0/filters:quality(75)/production/original_565125742.png
TCON $0.23 - cancer data readout this month - Market cap only $11 million this could be more than just a 10 bagger guys .check out the link below HC Wainwright has $6 price target for the stock
https://sih-st-charts.stocktwits-cdn.com/fit-in/500x0/filters:quality(75)/production/original_565125742.png
TCON $0.23 - data readout this month - Market cap only $11 million this could be more than just a 10 bagger guys .check out the link below HC Wainwright has $6 price target for the stock
https://sih-st-charts.stocktwits-cdn.com/fit-in/500x0/filters:quality(75)/production/original_565125742.png
TCON $0.24 --HC with $6 PT check out their analysis below
https://sih-st-charts.stocktwits-cdn.com/fit-in/500x0/filters:quality(75)/production/original_565125742.png
TCON $0.24 with buy rating check out link below
https://sih-st-charts.stocktwits-cdn.com/fit-in/500x0/filters:quality(75)/production/original_565125742.png
TCON $0.24 results from cancer drug imminent --market cap laughable 11 million
Upcoming milestones :
updated efficacy and safety results during this month
complete nvasarc enrollment expected in Q1
final results anticipated during Q3 . If data are positive BLA filing will follow in Q4 with potential FDA approval by mid next year
AMLX $3 drops 85% =good rebound play